Fasting Study of Metformin Hydrochloride ER Tablets 750 mg and Glucophage® XR Tablets 750 mg
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's metformin
hydrochloride ER tablets to Bristol-Myers Squibb's Glucophage® XR tablets following a single,
oral 750 mg (1 x 750 mg) dose administered under fasting conditions.